NICE okays Merck’s Keytruda, giving it parity with Opdivo for adjuvant melanoma
UNITED KINGDOM – Merk & Co’s checkpoint inhibitor Keytruda, which has been available for three...
Read More
Tag: Bristol-Myers Squibb
Sanofi inks megadeal with AI firm Exscientia to develop up to 15 new drugs
FRANCE – In a deal worth up to US$5.2 billion in milestone payments, French drugmaker Sanofi...
Read More
Merck has bagged another early cancer nod for Keytruda with FDA approval in post-surgery kidney cancer
USA – US Food and Drug Administration (USFDA) has approved Merck & Co.’s immunotherapy...
Read More
AI giant Exscientia files IPO, raises over US$460 million for drug research and development
UNITED KINGDOM – Exscientia’s initial public offering and private placement has raised...
Read More
LATEST DIGITAL MAGAZINE
